Although biologics targeting immunoglobulin E (IgE), interleukin-5 (IL-5)/IL-5 receptor alpha (IL-5Rα), and IL-4 receptor alpha (IL-4Rα) have improved type-2-high asthma, their efficacy in steroid-hyporesponsive disease remains limited, as they do not restore immune regulation or glucocorticoid sensitivity. This evidence concerns the gene IGHE and asthma.